Replimune Group Inc
REPL
7.33USD+0.58 (+8.59%)Market ClosedWatchlist
Market Summary
USD7.33+0.58
Market Closed8.59%
REPL Stock Price
View Fullscreen
REPL RSI Chart
REPL Valuation
REPL Price/Sales (Trailing)
REPL Profitability
REPL Fundamentals
REPL Revenue
REPL Earnings
Price Action
Last 7 days
-35.2%
Last 30 days
-43.0%
Last 90 days
-62.6%
Trailing 12 Months
-61.2%
How does REPL drawdown profile look like?
REPL Financial Health
REPL Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 9.7M | 15.6M | 21.1M | 0 |
| 2022 | 1.7M | 1.3M | 1.1M | 3.7M |
| 2021 | 2.8M | 2.9M | 2.9M | 2.4M |
| 2020 | 3.1M | 3.1M | 3.3M | 2.9M |
| 2019 | 2.8M | 3.3M | 3.2M | 2.6M |
| 2018 | 2.3M | 2.1M | 2.1M | 3.0M |
| 2017 | 0 | 0 | 0 | 0 |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for REPL
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Nov 16, 2023 | sarchi christopher | sold | -57,384 | 10.92 | -5,255 | chief commercial officer |
| Nov 16, 2023 | xynos konstantinos | sold | -79,858 | 10.92 | -7,313 | chief medical officer |
| Sep 18, 2023 | hill emily luisa | acquired | - | - | 83,330 | chief financial officer |
| Sep 12, 2023 | esposito pamela | sold | -6,000 | 20.00 | -300 | chief business officer |
| Sep 12, 2023 | esposito pamela | acquired | 990 | 3.3 | 300 | chief business officer |
| Sep 11, 2023 | esposito pamela | acquired | 17,681 | 3.3 | 5,358 | chief business officer |
| Sep 11, 2023 | esposito pamela | sold | -107,214 | 20.01 | -5,358 | chief business officer |
| Aug 22, 2023 | esposito pamela | acquired | 122,380 | 6.57957 | 18,600 | chief business officer |
| Aug 22, 2023 | esposito pamela | sold | -372,186 | 20.01 | -18,600 | chief business officer |
| Aug 11, 2023 | esposito pamela | sold | -28,000 | 20.00 | -1,400 | chief business officer |
Which funds bought or sold REPL recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Nov 24, 2023 | DEUTSCHE BANK AG\ | reduced | -86.19 | -2,824,680 | 320,094 | -% |
| Nov 22, 2023 | Graham Capital Management, L.P. | new | - | 339,924 | 339,924 | 0.01% |
| Nov 21, 2023 | Walleye Capital LLC | sold off | -100 | -1,176,400 | - | -% |
| Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | added | 13.88 | -428,589 | 2,235,630 | -% |
| Nov 15, 2023 | Tudor Investment Corp Et Al | sold off | -100 | -669,595 | - | -% |
| Nov 15, 2023 | MORGAN STANLEY | reduced | -28.18 | -7,145,050 | 8,030,730 | -% |
| Nov 15, 2023 | JANE STREET GROUP, LLC | sold off | -100 | -1,870,700 | - | -% |
| Nov 15, 2023 | CAPTRUST FINANCIAL ADVISORS | reduced | -3.4 | -296,997 | 733,437 | -% |
| Nov 14, 2023 | Voya Investment Management LLC | added | 1.75 | -95,980 | 287,568 | -% |
| Nov 14, 2023 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -4,228,620 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Replimune Group Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | price t rowe associates inc /md/ | 9.2% | 5,064,744 | SC 13G/A | |
| Feb 14, 2023 | redmile group, llc | 9.9% | 5,740,099 | SC 13G/A | |
| Feb 14, 2023 | baker bros. advisors lp | 9.99% | 5,768,227 | SC 13G | |
| Feb 13, 2023 | omega fund iv, l.p. | 7.2% | 3,610,478 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 5.5% | 3,010,552 | SC 13G | |
| Nov 18, 2022 | redmile group, llc | 9.9% | 5,165,131 | SC 13G/A | |
| Sep 14, 2022 | atlas venture fund x, l.p. | 4.4% | 2,164,037 | SC 13D/A | |
| Feb 14, 2022 | redmile group, llc | 9.9% | 4,775,461 | SC 13G/A | |
| Feb 14, 2022 | omega fund iv, l.p. | 10.6% | 5,012,052 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 12.5% | 5,868,638 | SC 13G/A |
Recent SEC filings of Replimune Group Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Dec 05, 2023 | 8-K | Current Report | |
| Nov 17, 2023 | 4 | Insider Trading | |
| Nov 17, 2023 | 4 | Insider Trading | |
| Nov 07, 2023 | 8-K | Current Report | |
| Nov 07, 2023 | 10-Q | Quarterly Report | |
| Sep 20, 2023 | 4 | Insider Trading | |
| Sep 20, 2023 | 3 | Insider Trading | |
| Sep 19, 2023 | 8-K | Current Report | |
| Sep 13, 2023 | 4 | Insider Trading | |
| Sep 07, 2023 | 8-K | Current Report |
Peers (Alternatives to Replimune Group Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.4B | - | 4.92% | 426363.59% | -3.6K | 218.4K | - | -102.45% |
MRNA | 30.7B | 10.7B | 11.84% | -53.56% | -8.86 | 2.88 | -53.67% | -129.46% |
ALNY | 22.0B | 1.7B | 4.71% | -20.32% | -43.06 | 12.74 | 79.37% | 56.87% |
BMRN | 17.7B | 2.3B | 23.54% | -7.88% | 120.62 | 7.68 | 15.05% | 75.21% |
INCY | 12.4B | 3.6B | 1.56% | -32.86% | 29.22 | 3.44 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.5B | 272.9M | 38.55% | 34.32% | -12.3 | 27.31 | 141.38% | 4.43% |
BBIO | 5.6B | - | 16.25% | 246.63% | -9.66 | 48.33 | 54.84% | -12.96% |
ACAD | 3.5B | 631.9M | -10.80% | 43.56% | -23.57 | 5.55 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 11.07% | -7.88% | -16.25 | 14.68 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.66% | -25.68% | -12.44 | 10.6 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 7.85% | -14.88% | 24.07 | 4.29 | 81.69% | -7.29% |
NVAX | 662.5M | 1.0B | -19.01% | -66.75% | -1.21 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | -2.56% | -78.77% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 42.3M | - | 410.00% | -4.38% | -0.65 | - | - | -29.23% |
CRBP | 26.3M | - | 17.86% | 4717.52% | -0.55 | - | - | -13.74% |
Replimune Group Inc News
Latest updates
Financials for Replimune Group Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | -2.2% | 6,049,000 | 6,186,000 | 6,145,000 | 2,675,000 | 574,000 | 343,000 | 131,000 | 87,000 | 725,000 | 788,000 | 816,000 | 550,000 | 755,000 | 686,000 | 859,000 | 951,000 | 620,000 | 687,000 | 325,500 | 1,577,000 | 664,000 |
| Operating Expenses | 14.7% | 63,831,000 | 55,648,000 | 52,995,000 | 41,630,000 | 41,579,000 | 40,876,000 | 31,988,000 | 29,698,000 | 29,247,000 | 27,381,000 | 22,184,000 | 20,275,000 | 19,663,000 | 17,833,000 | 16,385,000 | 16,664,000 | 12,242,000 | 10,907,000 | 7,826,000 | 10,137,000 | 7,104,000 |
| S&GA Expenses | -3.2% | 14,730,000 | 15,211,000 | 15,041,000 | 11,369,000 | 12,745,000 | 11,398,000 | 10,252,000 | 10,345,000 | 9,345,000 | 8,827,000 | 5,959,000 | 5,953,000 | 5,613,000 | 5,676,000 | 5,197,000 | 4,716,000 | 4,074,000 | 3,450,000 | 2,410,500 | 2,280,000 | 2,142,000 |
| R&D Expenses | 21.4% | 49,101,000 | 40,437,000 | 37,954,000 | 30,261,000 | 28,834,000 | 29,478,000 | 21,736,000 | 19,353,000 | 19,902,000 | 18,554,000 | 16,225,000 | 14,322,000 | 14,050,000 | 12,157,000 | 11,188,000 | 11,948,000 | 8,168,000 | 7,457,000 | 5,415,500 | 7,857,000 | 4,962,000 |
| EBITDA Margin | - | - | - | -16.95 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Expenses | -14.3% | 955,000 | 1,115,000 | 1,022,000 | 941,000 | - | - | - | - | - | - | 1,000 | 247,000 | 286,000 | 284,000 | - | 834,000 | 195,000 | - | - | - | - |
| Income Taxes | -200.0% | -200,000 | 200,000 | - | - | - | - | -55,000 | 12,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings Before Taxes | -22.1% | -60,245,000 | -49,354,000 | - | - | -43,102,000 | -42,253,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBT Margin | - | - | - | -17.39 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -21.1% | -60,044,000 | -49,600,000 | -49,238,000 | -39,690,000 | -43,102,000 | -42,300,000 | -31,696,000 | -29,674,000 | -29,355,000 | -27,311,000 | -21,499,000 | -21,783,000 | -20,095,000 | -17,493,000 | -15,789,000 | -16,189,000 | -11,139,000 | -9,508,000 | -6,656,000 | -7,673,000 | -6,461,000 |
| Net Income Margin | - | - | - | -17.42 | -37.05 | -25.61 | -41.13 | -37.22 | -35.22 | -34.72 | -31.17 | -28.81 | -27.59 | -22.26 | -20.64 | -17.06 | -15.24 | - | - | - | - | - |
| Free Cashflow | - | - | - | -33,047,000 | -29,144,000 | -33,606,000 | -34,523,000 | -23,709,000 | -18,813,000 | -23,389,000 | -18,605,000 | -16,898,000 | -13,607,000 | -17,254,000 | -16,022,000 | -12,600,000 | -19,791,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -6.9% | 562 | 604 | 647 | 679 | 436 | 459 | 461 | 485 | 503 | 524 | 543 | 559 | 314 | 330 | 234 | 250 | 151 | 144 | 154 | 152 | 154 |
| Current Assets | -7.6% | 508 | 550 | 593 | 624 | 379 | 402 | 404 | 428 | 444 | 465 | 484 | 499 | 252 | 268 | 174 | 191 | 118 | 128 | 141 | 145 | 152 |
| Cash Equivalents | -27.1% | 78.00 | 106 | 147 | 207 | 89.00 | 114 | 108 | 134 | 162 | 194 | 184 | 326 | 45.00 | 106 | 61.00 | 63.00 | 65.00 | 40.00 | 27.00 | 22.00 | 24.00 |
| Net PPE | 10.9% | 8.00 | 8.00 | 7.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 6.00 | 4.00 | 1.00 | 12.00 | 6.00 | 0.00 |
| Liabilities | 8.2% | 97.00 | 90.00 | 91.00 | 83.00 | 52.00 | 49.00 | 50.00 | 48.00 | 46.00 | 45.00 | 44.00 | 43.00 | 53.00 | 52.00 | 50.00 | 53.00 | 31.00 | 13.00 | 16.00 | 9.00 | 4.00 |
| Current Liabilities | 23.5% | 40.00 | 32.00 | 34.00 | 26.00 | 24.00 | 20.00 | 21.00 | 18.00 | 17.00 | 15.00 | 15.00 | 13.00 | 13.00 | 12.00 | 12.00 | 14.00 | 12.00 | 13.00 | 10.00 | 4.00 | 4.00 |
| Long Term Debt | 0.9% | 29.00 | 29.00 | 29.00 | 28.00 | - | - | - | - | - | - | - | - | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | - | - | - | - |
| LT Debt, Non Current | - | - | - | 29.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | -9.5% | 465 | 514 | 555 | 595 | 384 | 410 | 411 | 438 | 457 | 479 | 499 | 516 | 261 | 278 | 184 | 198 | 121 | 130 | 138 | 143 | 150 |
| Retained Earnings | -11.2% | -595 | -535 | -485 | -436 | -396 | -353 | -311 | -279 | -249 | -220 | -193 | -171 | -149 | -129 | -112 | -96.51 | -80.32 | -69.18 | -59.77 | -53.11 | -45.44 |
| Additional Paid-In Capital | 0.9% | 1,055 | 1,045 | 1,035 | 1,028 | 778 | 763 | 723 | 717 | 707 | 700 | 692 | 688 | 412 | 409 | 297 | 295 | 202 | 200 | 199 | 198 | 197 |
| Shares Outstanding | 0.1% | 59.00 | 59.00 | 57.00 | 57.00 | 50.00 | 54.00 | 47.00 | 52.00 | 52.00 | 52.00 | 47.00 | 49.00 | 44.00 | 40.00 | 37.00 | 33.00 | 32.00 | 32.00 | 32.00 | 32.00 | 25.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | 10.3% | -43,590 | -48,588 | -32,796 | -28,589 | -33,210 | -33,455 | -22,557 | -18,348 | -22,961 | -18,314 | -16,128 | -12,992 | -17,179 | -15,090 | -11,262 | -15,735 | -19,973 | -13,582 | -6,033 | -6,103 | -6,383 |
| Share Based Compensation | 3.0% | 9,115 | 8,846 | 6,922 | 7,023 | 6,992 | 7,194 | 5,773 | 5,918 | 6,313 | 6,250 | 3,472 | 3,049 | 2,801 | 2,468 | 1,806 | 2,344 | 1,781 | 1,810 | 907 | 880 | 718 |
| Cashflow From Investing | 72.3% | 12,683 | 7,361 | -22,752 | -125,101 | 36.00 | 5,315 | -4,326 | -13,420 | -11,052 | 26,992 | -126,273 | 31,421 | -44,798 | -49,126 | 7,841 | -65,209 | 25,324 | 26,811 | 10,474 | 3,801 | -85,109 |
| Cashflow From Financing | -60.4% | 438 | 1,105 | -77.00 | 271,435 | 7,423 | 32,522 | 359 | 3,969 | 1,150 | 1,120 | 785 | 262,198 | -35.00 | 109,514 | 34.00 | 90,364 | 9,750 | 18.00 | 41.00 | 153 | 101,391 |
REPL Income Statement
2023-09-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Operating expenses: | ||||
| Research and development | $ 49,101 | $ 28,834 | $ 89,538 | $ 58,312 |
| Selling, general and administrative | 14,730 | 12,745 | 29,941 | 24,143 |
| Total operating expenses | 63,831 | 41,579 | 119,479 | 82,455 |
| Loss from operations | (63,831) | (41,579) | (119,479) | (82,455) |
| Other income (expense): | ||||
| Research and development incentives | 443 | 574 | 836 | 1,425 |
| Investment income | 6,049 | 1,112 | 12,235 | 1,455 |
| Interest expense on finance lease liability | (542) | (550) | (1,086) | (1,102) |
| Interest expense on debt obligations | (955) | 0 | (2,070) | 0 |
| Other (expense) income | (1,409) | (2,659) | (35) | (4,678) |
| Total other income (expense), net | 3,586 | (1,523) | 9,880 | (2,900) |
| Loss before income taxes | (60,245) | (43,102) | (109,599) | (85,355) |
| Income tax (benefit) | (201) | 0 | 0 | 0 |
| Net loss | $ (60,044) | $ (43,102) | $ (109,599) | $ (85,355) |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | $ (0.90) | $ (0.79) | $ (1.65) | $ (1.57) |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | $ (0.90) | $ (0.79) | $ (1.65) | $ (1.57) |
| Weighted average common shares outstanding, basic (in shares) | 66,582,280 | 54,770,291 | 66,475,577 | 54,492,395 |
| Weighted average common shares outstanding, diluted (in shares) | 66,582,280 | 54,770,291 | 66,475,577 | 54,492,395 |
REPL Balance Sheet
2023-09-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2023 | Mar. 31, 2023 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 75,996 | $ 146,590 |
| Short-term investments | 420,765 | 436,796 |
| Research and development incentives receivable | 2,900 | 2,939 |
| Prepaid expenses and other current assets | 8,514 | 6,278 |
| Total current assets | 508,175 | 592,603 |
| Property, plant and equipment, net | 8,445 | 7,479 |
| Research and development incentives receivable, non-current | 809 | 0 |
| Restricted cash | 1,636 | 1,636 |
| Right-to-use asset - operating leases | 4,882 | 5,208 |
| Right-to-use asset - financing leases | 38,451 | 39,665 |
| Total assets | 562,398 | 646,591 |
| Current liabilities: | ||
| Accounts payable | 4,365 | 5,364 |
| Accrued expenses and other current liabilities | 31,651 | 24,704 |
| Operating lease liabilities, current | 1,138 | 1,118 |
| Financing lease liabilities, current | 2,678 | 2,639 |
| Total current liabilities | 39,832 | 33,825 |
| Operating lease liabilities, non-current | 4,052 | 4,389 |
| Financing lease liabilities, non-current | 23,709 | 23,965 |
| Long term debt, net of discount | 29,161 | 28,648 |
| Other liabilities, non-current | 472 | 472 |
| Total liabilities | 97,226 | 91,299 |
| Commitments and contingencies (Note 14) | ||
| Stockholders' equity | ||
| Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2023 and March 31, 2023; 59,059,343 and 56,676,313 shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively | 59 | 57 |
| Additional paid-in capital | 1,054,712 | 1,034,994 |
| Accumulated deficit | (595,087) | (485,488) |
| Accumulated other comprehensive income | 5,488 | 5,729 |
| Total stockholders' equity | 465,172 | 555,292 |
| Total liabilities and stockholders' equity | $ 562,398 | $ 646,591 |
| CEO | Mr. Philip Astley-Sparke F.S.A., FSA |
|---|---|
| WEBSITE | www.replimune.com |
| EMPLOYEES | 284 |